On September 10, 2026, Glucotrack, Inc. closed a private placement of senior secured convertible promissory notes with an aggregate principal amount of $11,596,172.68. The transaction generated gross cash proceeds of $4,500,000 and involved the exchange of approximately $4,545,015 in existing debt. Notes bear 8% annual interest, mature in nine months, and convert at a price equal to the lower of $3.12 or 80% of the 15-day VWAP, subject to a floor. Investors received warrants for 4,831,739 shares exercisable at $7.50 per share for five years. The financing includes registration rights and stockholder approval requirements capped at 19.99% of outstanding shares. Glucotrack operates in the medical device industry, focusing on continuous glucose monitoring systems.

Glucotrack, Inc. entered into a Settlement and Release Agreement on September 4, 2026, resolving disputes regarding approximately $10.9 million in indebtedness owed by Apimeds Pharmaceuticals US, Inc. to Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B. Under the agreement, Glucotrack is jointly obligated to pay an initial $2.0 million cash payment and issue a convertible promissory note for an additional $2.0 million. The note bears 5% annual interest and requires four quarterly principal installments of $500,000 beginning November 30, 2026. Alto may elect to convert the outstanding principal into common stock at $2.98 per share. Glucotrack operates in the healthcare sector, developing medical devices for diabetes management.

Glucotrack, Inc. filed a Certificate of Amendment to its Certificate of Incorporation with the Delaware Secretary of State, effecting a one-for-fifteen (1-for-15) reverse stock split effective August 28, 2026. The transaction was approved by stockholders at the annual meeting on August 18, 2026. Consequently, outstanding common shares decreased from approximately 11,972,157 to roughly 798,144, while authorized shares remained unchanged at 250,000,000. Stock options and warrants were adjusted proportionally with corresponding exercise price increases. The company will begin trading on a split-adjusted basis on August 31, 2026, under the same ticker symbol GCTK. Glucotrack operates in the healthcare technology sector, developing digital health solutions for diabetes management.

Glucotrack, Inc. filed an amendment to its Form 8-K to include financial statements and pro forma information regarding the reverse merger with Lokahi Therapeutics, Inc., which closed on July 14, 2026. Under the merger terms, Lokahi shareholders received shares of Glucotrack common stock and Series A convertible preferred stock, resulting in Lokahi holders owning 90% of the combined entity's fully diluted equity. The filing includes Lokahi’s unaudited condensed financials for the six months ended June 30, 2026, reporting a net loss of $8,098,087 and cash on hand of $53,186. Additionally, Glucotrack disclosed a confidential settlement agreement executed in April 2026 that resolved disputes with its former parent company, Apimeds Pharmaceuticals US, Inc., involving working capital contributions and the assumption of related party debt. Lokahi Therapeutics is a clinical-stage biopharmaceutical company developing LT-100, a bee venom-based therapy for knee osteoarthritis.

Glucotrack, Inc. held its 2026 annual meeting of stockholders on August 18, 2026, where shareholders approved a reverse stock split at an aggregate ratio not to exceed one-for-thirty and authorized a warrant inducement involving the repricing of existing warrants to comply with Nasdaq Listing Rule 5635(d). The company also elected six directors, ratified executive compensation on an advisory basis, and reappointed CBIZ CPAs P.C. as its independent auditor. Glucotrack operates in the medical device industry, developing continuous glucose monitoring systems.